HERCESSI Q Code: Q5146

Drug & Product Overview

HCPCS Descriptor Injection, trastuzumab-strf (hercessi), biosimilar, 10 mg

HCPCS Added Date January 1, 2025

Manufacturer Accord

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose, Multi-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About HERCESSI

Hercessi is a medication aligned to the HCPCS Q Code: Q5146 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Accord.

According to CMS Drug Use Information: Trastuzumab is used to treat certain types of breast, stomach, or esophagus cancer. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, trastuzumab-strf.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Package	Manufacturer	HCPCS Units	WAC	AWP
69448-0015-05	150 MG / 7.4 ML Hercessi Intravenous Injection 150 MG/7.4ML - 1 VIAL, SINGLE-DOSE in 1 CARTON (69448-015-05) / 7.4 mL in 1 VIAL, SINGLE-DOSE	Accord BioPharma Inc.	15	$1,323.00 $88.20 / unit	$1,587.60 $105.84 / unit
69448-0016-11	420 MG / 20 ML Hercessi Intravenous Injection 420 MG/20ML - 1 VIAL, MULTI-DOSE in 1 CARTON (69448-016-11) / 20 mL in 1 VIAL, MULTI-DOSE	Accord BioPharma Inc.	42	$3,704.40 $88.20 / unit	$4,445.28 $105.84 / unit
69448-0035-63	—	ACCORD BIOPHARMA INC.	42	$3,704.40 $88.20 / unit	$4,445.28 $105.84 / unit

Effective 1/1/25 (WAC & AWP)

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

HERCESSI Pricing & Reimbursement

Q5146 Private Payer Reimbursement

$39.44 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

NDC Package

HCPCS Units

Markup / Markdown

%

Common:

Estimates only. Payer reimbursement varies by contract, site of care, and sequestration.

Estimated Reimbursement

Trastuzumab Biosimilar Information:

HERCESSI Approval Date: April 25, 2024

Product Name	HCPCS Code	Active Ingredient	BLA Type
Herceptin	J9355	Trastuzumab	351(a) Originator Product
Ogivri	Q5114	Trastuzumab	351(k) Biosimilar
Herzuma	Q5113	Trastuzumab	351(k) Biosimilar
Ontruzant	Q5112	Trastuzumab	351(k) Biosimilar
Trazimera	Q5116	Trastuzumab	351(k) Biosimilar
Kanjinti	Q5117	Trastuzumab	351(k) Biosimilar
Hercessi	Q5146	Trastuzumab	351(k) Biosimilar

HERCESSI CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

HERCESSI Medically Unlikely Edits (MUE)

The most billing units of Q5146 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

120 units / day

= 1,200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

HERCESSI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Breast Cancer Gastric or Gastroesophageal Junction Adenocarcinoma

Drug Class

HER2/Neu/cerbB2 Antagonists [MoA]HER2/neu Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available HERCESSI billing and coding guide?

Billing and coding information for HERCESSI can be found through Accord Biopharma. Visit Here →

What are the available HERCESSI patient assistance programs?

HERCESSI patient assistance information can be found through Accord Biopharma. Visit Here →

Where can I find HERCESSI prescribing information?

HERCESSI prescribing information can be found at the link below. Visit Here →

Where can I find HERCESSI side effect information?

HERCESSI side effect information can be found through MedlinePlus at the link below.

Does billing HERCESSI require JZ/JW wastage modifiers?

CMS does not include HERCESSI (Q5146) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5146. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.